3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
4
Neoplasms
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Sepsis
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Diseases
1
Graft vs Host Disease
1
Gliosarcoma
1
Glioblastoma
1
Fever
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Interventions
Temozolomide
8
Radiotherapy
6
Procarbazine
4
Radiation
3
Lomustine
3
Carmustine
3
Dihematoporphyrin Ether
2
sargramostim
1
rindopepimut
1
depatuxizumab mafodotin
1
Vincristine
1
Surgical Procedures, Operative
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Radiosurgery
1
Photons
1
O(6)-benzylguanine
1
Neoadjuvant Therapy
1
Methylphenidate
1
Magnetic Resonance Spectroscopy
1
Leflunomide
1
Isotretinoin
1
Immunoglobulin G
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fentanyl
1
Donepezil
1
Disulfides
1
DNA Methylation
1
Chemotherapy, Adjuvant
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Gliosarcoma
×
Granulocyte-Macrophage Colony-Stimulating Factor
×
Clear all
NCT01480479
2018-01-16
ACT IV
Celldex Therapeutics
Phase 3
Completed
745 enrolled